{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:22:04Z","timestamp":1793312524095,"version":"4.5.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA255323-01A1"],"award-info":[{"award-number":["R01CA255323-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110675"],"award-info":[{"award-number":["W81XWH2110675"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bbcan.2025.189267","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:31:44Z","timestamp":1737448304000},"page":"189267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["An overview of BAP1 biological functions and current therapeutics"],"prefix":"10.1016","volume":"1880","author":[{"given":"Abdelrahman M.","family":"Elsayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muaiad","family":"Kittaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Cebulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0005","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.bbcan.2025.189267_bb0020","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405231121","article-title":"Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling","volume":"121","author":"Novelli","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","article-title":"Gene of the month: BAP1","volume":"69","author":"Wang","year":"2016","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41420-021-00406-2","article-title":"Emerging multifaceted roles of BAP1 complexes in biological processes","volume":"7","author":"Szczepanski","year":"2021","journal-title":"Cell Death Dis."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189267_bb0035","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","article-title":"BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization","volume":"68","author":"Ventii","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189267_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"7010","key":"10.1016\/j.bbcan.2025.189267_bb0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nature02985","article-title":"Role of histone H2A ubiquitination in Polycomb silencing","volume":"431","author":"Wang","year":"2004","journal-title":"Nature"},{"issue":"6290","key":"10.1016\/j.bbcan.2025.189267_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad9780","article-title":"Epigenetic balance of gene expression by Polycomb and COMPASS families","volume":"352","author":"Piunti","year":"2016","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0055","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1101\/gr.261016.120","article-title":"PR-DUB maintains the expression of critical genes through FOXK1\/2- and ASXL1\/2\/3-dependent recruitment to chromatin and H2AK119ub1 deubiquitination","volume":"30","author":"Kolovos","year":"2020","journal-title":"Genome Res."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0060","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov."},{"issue":"7659","key":"10.1016\/j.bbcan.2025.189267_bb0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated ca(2+) flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.molcel.2014.03.002","article-title":"Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O","volume":"54","author":"Mashtalir","year":"2014","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0075","doi-asserted-by":"crossref","first-page":"556","DOI":"10.21037\/jgo.2016.03.05","article-title":"BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype","volume":"7","author":"Al-Shamsi","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0090","first-page":"429","article-title":"Clear cell renal cell carcinoma with BAP1 mutation: a report of two cases","volume":"11","author":"Lee","year":"2023","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189267_bb0095","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189267_bb0100","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189267_bb0105","doi-asserted-by":"crossref","unstructured":"H. Yu, H. Pak, I. Hammond-Martel, M. Ghram, A. Rodrigue, S. Daou, H. Barbour, L. Corbeil, J. H\u00e9bert, E. Drobetsky, J.Y. Masson, J.M. Di Noia, B. Affar el, tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair, Proc. Natl. Acad. Sci. USA 111(1) (2014) 285\u201390.","DOI":"10.1073\/pnas.1309085110"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189267_bb0110","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41418-022-01024-w","article-title":"BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability","volume":"29","author":"Lee","year":"2022","journal-title":"Cell Death Differ"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0115","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.molcel.2015.06.006","article-title":"PARPs and ADP-Ribosylation: 50 years \u2026 and counting","volume":"58","author":"Kraus","year":"2015","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0120","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189267_bb0125","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41388-024-02966-w","article-title":"The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK","volume":"43","author":"Sato","year":"2024","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0130","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41419-018-0500-6","article-title":"BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma","volume":"9","author":"Sime","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189267_bb0135","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.30224","article-title":"Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells","volume":"7","author":"Kolluri","year":"2018","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0140","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0145","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","article-title":"BAP1 links metabolic regulation of ferroptosis to tumour suppression","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/path.5384","article-title":"Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development","volume":"250","author":"Figueiredo","year":"2020","journal-title":"J. Pathol."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189267_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153678","article-title":"BAP1 loss promotes suppressive tumor immune microenvironment via upregulation of PROS1 in class 2 uveal melanomas","volume":"14","author":"Kaler","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"37","key":"10.1016\/j.bbcan.2025.189267_bb0160","doi-asserted-by":"crossref","first-page":"25750","DOI":"10.1074\/jbc.M114.569020","article-title":"Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation","volume":"289","author":"Tsou","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189267_bb0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124184","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12974-020-02041-7","article-title":"Mer regulates microglial\/macrophage M1\/M2 polarization and alleviates neuroinflammation following traumatic brain injury","volume":"18","author":"Wu","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102832","article-title":"Transcriptome profiling reveals new insights into the immune microenvironment and upregulation of novel biomarkers in metastatic uveal melanoma","volume":"12","author":"Krishna","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0185","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41467-019-14256-1","article-title":"Single-cell analysis reveals new evolutionary complexity in uveal melanoma","volume":"11","author":"Durante","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0190","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/1521-4141(200102)31:2<459::AID-IMMU459>3.0.CO;2-Y","article-title":"Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells","volume":"31","author":"Speiser","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2025.189267_bb0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61737-979-6_1","article-title":"Regulatory T cells: history and perspective","volume":"707","author":"Sakaguchi","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbcan.2025.189267_bb0200","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3389\/fimmu.2018.02788","article-title":"Human CD8(+)HLA-DR(+) regulatory T cells, similarly to classical CD4(+)Foxp3(+) cells, suppress immune responses via PD-1\/PD-L1 Axis","volume":"9","author":"Machicote","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189267_bb0205","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","article-title":"Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment","volume":"66","author":"Gezgin","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081102","article-title":"Loss of BAP1 is associated with upregulation of the NFkB pathway and increased HLA class I expression in uveal melanoma","volume":"11","author":"Souri","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000228","article-title":"CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma","volume":"8","author":"Zhou","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0220","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0225","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.celrep.2016.05.096","article-title":"NeuCode proteomics reveals Bap1 regulation of metabolism","volume":"16","author":"Baughman","year":"2016","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0230","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41388-020-01554-y","article-title":"BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors","volume":"40","author":"Han","year":"2021","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0235","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0240","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/PAS.0b013e3182498be5","article-title":"A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression","volume":"36","author":"Wiesner","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0245","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jtho.2021.08.765","article-title":"Meningiomas in patients with malignant pleural mesothelioma harboring germline BAP1 mutations","volume":"17","author":"Hu","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.canlet.2015.09.011","article-title":"Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction","volume":"369","author":"Cheung","year":"2015","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189267_bb0260","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189267_bb0265","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0270","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22424","article-title":"Germline BAP1 alterations in familial uveal melanoma","volume":"56","author":"Rai","year":"2017","journal-title":"Genes Chromosom. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189267_bb0275","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41431-023-01448-z","article-title":"Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome","volume":"31","author":"Lalloo","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.bbcan.2025.189267_bb0280","series-title":"GeneReviews(\u00ae)","article-title":"BAP1 tumor predisposition syndrome","author":"Pilarski","year":"1993"},{"key":"10.1016\/j.bbcan.2025.189267_bb0285","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.12.022","article-title":"Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy","volume":"92","author":"Star","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"35","key":"10.1016\/j.bbcan.2025.189267_bb0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189267_bb0295","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0300","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 is a Bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0305","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PGP.0000000000000855","article-title":"BAP1 tumor predisposition syndrome presenting as a recurrent ovarian sex cord-stromal tumor","volume":"42","author":"Albright","year":"2023","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"6009","key":"10.1016\/j.bbcan.2025.189267_bb0310","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189267_bb0315","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2022.04.013","article-title":"In uveal melanoma G\u03b1-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than G\u03b1-protein GNAQ mutations","volume":"170","author":"Piaggio","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0320","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0325","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0330","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189267_bb0335","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"issue":"47","key":"10.1016\/j.bbcan.2025.189267_bb0340","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0345","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0350","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/gcc.22752","article-title":"Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer","volume":"58","author":"Boru","year":"2019","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.bbcan.2025.189267_bb0355","series-title":"BAP1 tumor predisposition syndrome","author":"Robert Pilarski","year":"2024"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189267_bb0360","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41588-024-01799-3","article-title":"Saturation genome editing of BAP1 functionally classifies somatic and germline variants","volume":"56","author":"Waters","year":"2024","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0365","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/hmg\/ddad193","article-title":"Functional assay for assessment of pathogenicity of BAP1 variants","volume":"33","author":"Repo","year":"2024","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0370","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0375","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0380","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189267_bb0385","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis","year":"2012","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0390","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035295","article-title":"Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families","volume":"7","author":"Njauw","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0400","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0405","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0410","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"issue":"7353","key":"10.1016\/j.bbcan.2025.189267_bb0415","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Integrated genomic analyses of ovarian carcinoma","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0420","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0425","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/s41467-018-03828-2","article-title":"Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers","volume":"9","author":"Guo","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ng.2983","article-title":"Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer","volume":"46","author":"Wang","year":"2014","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0435","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.2591","article-title":"Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity","volume":"45","author":"Dulak","year":"2013","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0440","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat. Genet."},{"issue":"7511","key":"10.1016\/j.bbcan.2025.189267_bb0445","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189267_bb0450","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/ncomms6006","article-title":"Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes","volume":"5","author":"Jones","year":"2014","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0455","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng.3525","article-title":"Nikolaev, genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","volume":"48","author":"Bonilla","year":"2016","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0460","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ajhg.2021.12.011","article-title":"Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder","volume":"109","author":"K\u00fcry","year":"2022","journal-title":"Am. J. Hum. Genet."},{"issue":"28","key":"10.1016\/j.bbcan.2025.189267_bb0465","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189267_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005633","article-title":"Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing Back nine generations to a common ancestor from the 1700s","volume":"11","author":"Carbone","year":"2015","journal-title":"PLoS Genet."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189267_bb0475","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1158\/0008-5472.CAN-04-0255","article-title":"Modern criteria to establish human cancer etiology","volume":"64","author":"Carbone","year":"2004","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189267_bb0480","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0485","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/2767-9764.CRC-23-0423","article-title":"Low exposures to amphibole or serpentine Asbestos in germline Bap1-mutant mice induce mesothelioma characterized by an immunosuppressive tumor microenvironment","volume":"4","author":"Kadariya","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189267_bb0490","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"issue":"41","key":"10.1016\/j.bbcan.2025.189267_bb0495","doi-asserted-by":"crossref","first-page":"25543","DOI":"10.1073\/pnas.2007622117","article-title":"Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy","volume":"117","author":"Xue","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"39","key":"10.1016\/j.bbcan.2025.189267_bb0500","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307999120","article-title":"HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma","volume":"120","author":"Suarez","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"48","key":"10.1016\/j.bbcan.2025.189267_bb0505","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111946118","article-title":"BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene \u00d7 environment interaction with asbestos","volume":"118","author":"Novelli","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0510","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/pcmr.12735","article-title":"The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma","volume":"32","author":"Webster","year":"2019","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0515","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0520","doi-asserted-by":"crossref","first-page":"100915","DOI":"10.1016\/j.xcrm.2022.100915","article-title":"Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma","volume":"4","author":"Pandey","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189267_bb0525","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189267_bb0530","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.7150\/jca.26275","article-title":"EZH2 expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis","volume":"9","author":"Sun","year":"2018","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0535","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-020-01173-x","article-title":"Verification of EZH2 as a druggable target in metastatic uveal melanoma","volume":"19","author":"Jin","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189267_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1013475","article-title":"EZH2-mediated H3K27me3 is a predictive biomarker and therapeutic target in uveal melanoma","volume":"13","author":"Hou","year":"2022","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0545","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nm.4098","article-title":"Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status","volume":"22","author":"Schoumacher","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189267_bb0550","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/1471-2407-13-371","article-title":"BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma","volume":"13","author":"Matatall","year":"2013","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0555","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nm.4094","article-title":"Reply to \u201cuveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status\u201d","volume":"22","author":"LaFave","year":"2016","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189267_bb0560","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41416-024-02661-3","article-title":"Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma","volume":"130","author":"Landman","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0565","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2767-9764.CRC-23-0276","article-title":"Combined inhibition of EZH2 and FGFR is synergistic in BAP1-deficient malignant mesothelioma","volume":"4","author":"Badhai","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0570","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0575","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0580","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-05-2766","article-title":"Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo","volume":"12","author":"Wakchoure","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189267_bb0585","first-page":"39","article-title":"A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma","volume":"8","author":"Jamil","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0590","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLC.2006.n.003","article-title":"Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid","volume":"7","author":"Krug","year":"2006","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0595","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"37","key":"10.1016\/j.bbcan.2025.189267_bb0600","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.bbcan.2025.189267_bb0605","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","article-title":"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors","volume":"6","author":"Sacco","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0610","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0615","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1541-7786.MCR-20-0434","article-title":"Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity Spectrum for BAP1-mutant uveal melanoma","volume":"19","author":"Kuznetsoff","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0620","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax1738","article-title":"BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers","volume":"5","author":"Kuznetsov","year":"2019","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0625","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat. Commun."},{"issue":"7035","key":"10.1016\/j.bbcan.2025.189267_bb0630","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189267_bb0635","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189267_bb0640","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0645","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189267_bb0650","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by Temozolomide in cells with high-Schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060751","article-title":"PARP inhibition increases the response to chemotherapy in uveal melanoma","volume":"11","author":"de Koning","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0660","article-title":"Phase 2 study of Olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2025.189267_bb0665","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2022.40.16_suppl.3122","article-title":"Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms","volume":"40","author":"George","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0670","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0675","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41420-021-00554-5","article-title":"Platinum drugs and taxanes: can we overcome resistance?","volume":"7","author":"Sazonova","year":"2021","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189267_bb0680","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191257","article-title":"Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice","volume":"217","author":"Badhai","year":"2020","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189267_bb0685","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and Pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189267_bb0690","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1002\/1878-0261.13322","article-title":"Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment","volume":"16","author":"Hariharan","year":"2022","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0695","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","article-title":"Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma","volume":"27","author":"Oehl","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0700","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0705","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189267_bb0710","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189267_bb0715","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189267_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124327","article-title":"Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review","volume":"21","author":"Panou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189267_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.603223","article-title":"BAP1-altered malignant pleural mesothelioma: outcomes with chemotherapy, immune check-point inhibitors and poly(ADP-ribose) polymerase inhibitors","volume":"11","author":"Dudnik","year":"2021","journal-title":"Front. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189267_bb0730","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189267_bb0735","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the real-world results from Australia, immunotherapy is not a good option for patients with mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189267_bb0740","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/2159-8290.CD-17-1246","article-title":"An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors","volume":"8","author":"Wang","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0745","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00262-023-03424-4","article-title":"BAP1-related signature predicts benefits from immunotherapy over VEGFR\/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN renal 101 and checkmate-009\/010\/025 trials","volume":"72","author":"Liu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189267_bb0750","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000480640","article-title":"Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013)","volume":"4","author":"Aronow","year":"2018","journal-title":"Ocul. Oncol. Pathol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189267_bb0755","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0161-6420(00)00182-2","article-title":"Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment","volume":"107","author":"Eskelin","year":"2000","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189267_bb0760","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0765","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000482","article-title":"New emerging targets in cancer immunotherapy: the role of LAG3","volume":"4","author":"Puhr","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2025.189267_bb0770","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2018.12.004","article-title":"Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma","volume":"127","author":"Kumar","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0775","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1535-7163.MCT-19-0356","article-title":"Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated protein 1 induces chemoresistance to ribonucleotide reductase inhibition","volume":"19","author":"Okonska","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189267_bb0780","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020429","article-title":"BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment","volume":"20","author":"Guazzelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189267_bb0785","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.628332","article-title":"The TRAIL in the treatment of human cancer: an update on clinical trials","volume":"8","author":"Snajdauf","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbcan.2025.189267_bb0790","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.30224","article-title":"Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells","volume":"7","author":"Kolluri","year":"2018","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189267_bb0795","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41419-018-1087-7","article-title":"BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1\/2 and JNK\/c-Jun pathways","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189267_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.567289","article-title":"Case report: BAP1 mutation and RAD21 amplification as predictive biomarkers to PARP inhibitor in metastatic intrahepatic cholangiocarcinoma","volume":"10","author":"Sabbatino","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189267_bb0805","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.927250","article-title":"Clinical benefit of Niraparib to TKI\/mTORi-resistance metastatic ccRCC with BAP1-frame shift mutation: case report and literature review","volume":"12","author":"Lian","year":"2022","journal-title":"Front. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.bbcan.2025.189301","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T01:49:35Z","timestamp":1748656175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":161,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0304419X25000095"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189267","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bbcan.2025.189301","asserted-by":"object"}]},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of BAP1 biological functions and current therapeutics","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189267"}}